Azapropazone (BioDeep_00000858624)
代谢物信息卡片
Azapropazone
化学式: C16H20N4O2 (300.158618)
中文名称: 阿扎丙宗
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCCC1C(=O)N2C3=C(C=CC(=C3)C)N=C(N2C1=O)N(C)C
InChI: InChI=1S/C16H20N4O2/c1-5-6-11-14(21)19-13-9-10(2)7-8-12(13)17-16(18(3)4)20(19)15(11)22/h7-9,11H,5-6H2,1-4H3
描述信息
M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic
D018501 - Antirheumatic Agents > D006074 - Gout Suppressants > D014528 - Uricosuric Agents
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents
D002491 - Central Nervous System Agents > D000700 - Analgesics
D000893 - Anti-Inflammatory Agents
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:38010
- KEGGdrug: D02966
- PubChem: 26098
- ChEMBL: CHEMBL1565476
- MeSH: Apazone
- CAS: 13539-59-8
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology.
2019 11; 96(5):629-640. doi:
10.1124/mol.119.115964. [PMID: 31515284] - R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals.
2008 Jul; 36(7):1385-405. doi:
10.1124/dmd.108.020479. [PMID: 18426954] - Hee Seung Kim, John Austin, David S Hage. Screening major binding sites on human serum albumin by affinity capillary electrophoresis.
Methods in molecular biology (Clifton, N.J.).
2004; 276(?):169-87. doi:
10.1385/1-59259-798-x:169. [PMID: 15163858] - A Chattopadhyay, T Tian, L Kortum, D S Hage. Development of tryptophan-modified human serum albumin columns for site-specific studies of drug-protein interactions by high-performance affinity chromatography.
Journal of chromatography. B, Biomedical sciences and applications.
1998 Sep; 715(1):183-90. doi:
10.1016/s0378-4347(98)00140-6. [PMID: 9792509] - D Pallapies, B A Peskar, K Brune, G Geisslinger. Effects on platelet functions and pharmacokinetics of azapropazone and ketorolac tromethamine given as single parenteral doses.
British journal of clinical pharmacology.
1994 Apr; 37(4):335-9. doi:
10.1111/j.1365-2125.1994.tb04286.x. [PMID: 8018454] - K D Rainsford, C James, D M Johnson, P I Stetsko, R E Hill, B J Salena, R H Hunt. Effects of chronic NSAIDs on gastric mucosal injury related to mucosal prostanoids, and plasma drug concentrations in human volunteers.
Agents and actions.
1993; 39 Spec No(?):C21-3. doi:
10.1007/bf01972708. [PMID: 8273571] - A Viani, G M Pacifici. Quantitative contribution of endogenous compounds and hypoalbuminemia in reducing the binding of furosemide in the plasma of newborn infants.
Developmental pharmacology and therapeutics.
1992; 18(1-2):39-43. doi:
10.1159/000480596. [PMID: 1483361] - R M Knabb, D E Rasbach, A W Leamy, D P Fernando, W M Mackin, G A Boswell, P B Timmermans, M J Thoolen. Persistent cardioprotection by azapropazone in a canine model of coronary artery thrombosis and thrombolysis.
Journal of cardiovascular pharmacology.
1991 Mar; 17(3):390-6. doi:
10.1097/00005344-199103000-00006. [PMID: 1711599] - F Brée, S Urien, P Nguyen, P Riant, E Albengres, J P Tillement. A re-evaluation of the HSA-piroxicam interaction.
European journal of drug metabolism and pharmacokinetics.
1990 Oct; 15(4):303-7. doi:
10.1007/bf03190219. [PMID: 2088766] - S A Mousa, R Brown, Y Chan, J Hsieh, R D Smith. Evaluation of the effect of azapropazone on neutrophil migration in anaesthetized swine using a multichamber blister suction technique.
British journal of pharmacology.
1990 Feb; 99(2):233-6. doi:
10.1111/j.1476-5381.1990.tb14686.x. [PMID: 2158370] - R Bald, E M Bernbeck-Betthäuser, H Spahn, E Mutschler. Excretion of azapropazone in human breast milk.
European journal of clinical pharmacology.
1990; 39(3):271-3. doi:
10.1007/bf00315109. [PMID: 2257865] - U Kragh-Hansen. Evidence for a large and flexible region of human serum albumin possessing high affinity binding sites for salicylate, warfarin, and other ligands.
Molecular pharmacology.
1988 Aug; 34(2):160-71. doi:
. [PMID: 3412320] - R C Fraser, R H Davis, F S Walker. Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia.
The Journal of the Royal College of General Practitioners.
1987 Sep; 37(302):409-11. doi:
NULL. [PMID: 3330140] - H Spahn, K Thabe, E Mutschler, K Tillmann, I Gikalov. Concentration of azapropazone in synovial tissues and fluid.
European journal of clinical pharmacology.
1987; 32(3):303-7. doi:
10.1007/bf00607579. [PMID: 3595703] - S Urien, E Albengres, J L Pinquier, J P Tillement. Role of alpha-1 acid glycoprotein, albumin, and nonesterified fatty acids in serum binding of apazone and warfarin.
Clinical pharmacology and therapeutics.
1986 Jun; 39(6):683-9. doi:
10.1038/clpt.1986.119. [PMID: 3709033] - S I Schlegel, H E Paulus. Non-steroidal and analgesic therapy in the elderly.
Clinics in rheumatic diseases.
1986 Apr; 12(1):245-73. doi:
10.1016/s0307-742x(21)00629-9. [PMID: 2872994] - D H Adams, A J Howie, J Michael, B McConkey, P A Bacon, D Adu. Non-steroidal anti-inflammatory drugs and renal failure.
Lancet (London, England).
1986 Jan; 1(8472):57-60. doi:
10.1016/s0140-6736(86)90714-2. [PMID: 2867313] - L K Atkinson, T H Goodship, M K Ward. Acute renal failure associated with acute pyelonephritis and consumption of non-steroidal anti-inflammatory drugs.
British medical journal (Clinical research ed.).
1986 Jan; 292(6513):97-8. doi:
10.1136/bmj.292.6513.97-a. [PMID: 3080108] - K J Fehske, W E Müller. High-affinity binding of ethacrynic acid is mediated by the two most important drug binding sites of human serum albumin.
Pharmacology.
1986; 32(4):208-13. doi:
10.1159/000138171. [PMID: 3714803] - R Sipilä, B Skrifvars, T Törnroth. Reversible non-oliguric impairment of renal function during azapropazone treatment.
Scandinavian journal of rheumatology.
1986; 15(1):23-6. doi:
10.3109/03009748609092664. [PMID: 3961430] - K D Rainsford. Distribution of azapropazone and its principal 8-hydroxy-metabolite in plasma, urine and gastrointestinal mucosa determined by HPLC.
The Journal of pharmacy and pharmacology.
1985 May; 37(5):341-5. doi:
10.1111/j.2042-7158.1985.tb05078.x. [PMID: 2862244] - P J Williamson, M D Ene, C J Roberts. A study of the potential interactions between azapropazone and frusemide in man.
British journal of clinical pharmacology.
1984 Oct; 18(4):619-23. doi:
10.1111/j.1365-2125.1984.tb02515.x. [PMID: 6487503] - C S Higgens, J T Scott. The uricosuric action of azapropazone: dose-response and comparison with probenecid.
British journal of clinical pharmacology.
1984 Sep; 18(3):439-43. doi:
10.1111/j.1365-2125.1984.tb02486.x. [PMID: 6487482] - F Hervé, K Rajkowski, M T Martin, P Dessen, N Cittanova. Drug-binding properties of rat alpha 1-foetoprotein. Binding of warfarin, phenylbutazone, azapropazone, diazepam, digitoxin and cholic acid.
The Biochemical journal.
1984 Jul; 221(2):401-6. doi:
10.1042/bj2210401. [PMID: 6206846] - T Gibson, H A Simmonds, R D Armstrong, L D Fairbanks, A V Rodgers. Azapropazone--a treatment for hyperuricaemia and gout?.
British journal of rheumatology.
1984 Feb; 23(1):44-51. doi:
10.1093/rheumatology/23.1.44. [PMID: 6697072] - D P Geaney, J G Carver, C L Davies, J K Aronson. Pharmacokinetic investigation of the interaction of azapropazone with phenytoin.
British journal of clinical pharmacology.
1983 Jun; 15(6):727-34. doi:
10.1111/j.1365-2125.1983.tb01557.x. [PMID: 6871071] - P F Gulyassy, T A Depner. Impaired binding of drugs and endogenous ligands in renal diseases.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
1983 May; 2(6):578-601. doi:
10.1016/s0272-6386(83)80038-9. [PMID: 6342372] - R Sipilä, B Kuhlbäck, B Skrifvars. Acute renal failure during azopropazone therapy.
Mayo Clinic proceedings.
1983 Mar; 58(3):209-10. doi:
NULL. [PMID: 6827866] - B J Kline, J H Wood, L A Beightol. The determination of azapropazone and its 6-hydroxy metabolite in plasma and urine by HPLC.
Arzneimittel-Forschung.
1983; 33(4):504-6. doi:
NULL. [PMID: 6683526] - H Spahn, E Mutschler. [HPLC determination of azapropazone in human plasma].
Archiv der Pharmazie.
1983 Jan; 316(1):42-7. doi:
10.1002/ardp.19833160110. [PMID: 6830416] - A L Thomas, F L Majoos, G Nuki. Preliminary studies with azapropazone in gout and hyperuricaemia.
European journal of rheumatology and inflammation.
1983; 6(2):149-54. doi:
NULL. [PMID: 6673978] - J S Templeton. Azapropazone or allopurinol in the treatment of chronic gout and/or hyperuricaemia. A preliminary report.
The British journal of clinical practice.
1982 Oct; 36(10):353-8. doi:
NULL. [PMID: 7171423] - A E Ritch, W N Perera, C J Jones. Pharmacokinetics of azapropazone in the elderly.
British journal of clinical pharmacology.
1982 Jul; 14(1):116-9. doi:
10.1111/j.1365-2125.1982.tb04947.x. [PMID: 7104163] - K J Fehske, U Schläfer, U Wollert, W E Müller. Characterization of an important drug binding area on human serum albumin including the high-affinity binding sites of warfarin and azapropazone.
Molecular pharmacology.
1982 Mar; 21(2):387-93. doi:
NULL. [PMID: 6808349] - I Gikalov, R Kaufmann, O Schuster. [Human pharmacokinetics of different i.v. doses of azapropazone (HPLC-determination) (author's transl)].
Arzneimittel-Forschung.
1982; 32(4):423-6. doi:
NULL. [PMID: 7201814] - K J Fehske, W E Müller, U Wollert. The location of drug binding sites in human serum albumin.
Biochemical pharmacology.
1981 Apr; 30(7):687-92. doi:
10.1016/0006-2952(81)90151-9. [PMID: 7018498] - E Jähnchen, K J Blanck, K H Breuing, H J Gilfrich, T Meinertz, D Trenk. Plasma protein binding of azapropazone in patients with kidney and liver disease.
British journal of clinical pharmacology.
1981 Apr; 11(4):361-7. doi:
10.1111/j.1365-2125.1981.tb01133.x. [PMID: 7259929] - P A Dieppe, M Doherty, J T Whicher, G Walters. The treatment of gout with azapropazone: clinical and experimental studies.
European journal of rheumatology and inflammation.
1981; 4(3):392-400. doi:
NULL. [PMID: 6242962] - K H Breuing, H J Gilfrich, T Meinertz, U W Wiegand, E Jähnchen. Disposition of azapropazone in chronic renal and hepatic failure.
European journal of clinical pharmacology.
1981; 20(2):147-55. doi:
10.1007/bf00607152. [PMID: 7262176] - K J Fehske, E Jähnchen, W E Müller, A Stillbauer. Azapropazone binding to human serum albumin.
Naunyn-Schmiedeberg's archives of pharmacology.
1980 Aug; 313(2):159-63. doi:
10.1007/bf00498574. [PMID: 7422015] - G Faust-Tinnefeldt, H E Geissler, H J Gilfrich. [Plasma level of azapropazone during its combined administration with digitoxin].
Die Medizinische Welt.
1979 Feb; 30(5):181-2. doi:
NULL. [PMID: 310503] - K H Breuing, H J Gilfrich, T Meinertz, E Jähnchen. Pharmacokinetics of azapropazone following single oral and intravenous doses.
Arzneimittel-Forschung.
1979; 29(6):971-2. doi:
NULL. [PMID: 582795] - J C McElnay, P F D'Arcy. The effect of azapropazone on the binding of warfarin to human serum proteins [proceedings].
The Journal of pharmacy and pharmacology.
1978 Dec; 30 Suppl(?):73P. doi:
10.1111/j.2042-7158.1978.tb10780.x. [PMID: 32332] - J S Templeton. Azapropazone and renal function.
Rheumatology and rehabilitation.
1978 Nov; 17(4):219-21. doi:
10.1093/rheumatology/17.4.219. [PMID: 734316] - J C McElnay, P F D'Arcy. Interaction between azapropazone and warfarin.
Experientia.
1978 Oct; 34(10):1320-1. doi:
10.1007/bf01981445. [PMID: 738406] - G Faust-Tinnefeldt, H E Geissler, H J Gilfrich. [Plasma azapropazone level during combination therapy of rheumatoid diseases].
Verhandlungen der Deutschen Gesellschaft fur Innere Medizin.
1978; ?(84):1502-5. doi:
NULL. [PMID: 311119] - H E Geissler, G Faust-Tinnefeldt, E Mutschler. [Determination of azapropazone and 8-hydroxyazapropazone in urine by direct quantitative thin-layer chromatography (author's transl)].
Arzneimittel-Forschung.
1978; 28(8):1430-1. doi:
NULL. [PMID: 582413] - J C McElnay, P F D'Arcy. Interaction between azapropazone and warfarin.
British medical journal.
1977 Sep; 2(6089):773-4. doi:
10.1136/bmj.2.6089.773-c. [PMID: 912313] - R J Ancill. Plasma exchange in severe rhesus disease.
British medical journal.
1977 Jun; 1(6074):1469-70. doi:
10.1136/bmj.1.6074.1469-b. [PMID: 861696] - G Faust-Tinnefeldt, H J Gilfrich. [Kinetics of digitoxin during antirheumatic therapy with azapropazone (author's transl)].
Arzneimittel-Forschung.
1977; 27(10):2009-11. doi:
NULL. [PMID: 579114] - H E Geissler, E Mutschler, G Faust-Tinnefeldt. [On the determination of azapropazone from plasma by direct quantitative thin-layer chromatography (author's transl)].
Arzneimittel-Forschung.
1977; 27(9):1713-5. doi:
NULL. [PMID: 579143] - G Faust-Tinnefeldt, H E Geissler, E Mutschler. [Azapropazone plasma levels under simultaneous treatment with an antacid or laxative].
Arzneimittel-Forschung.
1977; 27(12):2411-4. doi:
NULL. [PMID: 580058] - G Faust-Tinnefeldt, H E Geissler, E Mutschler. [Azapropazone plasma levels in rheumatologic therapy with D-penicillamine combined with immunosuppressive agents].
Arzneimittel-Forschung.
1977; 27(11):2153-7. doi:
NULL. [PMID: 580020] - S Thune. A comparative study of azapropazone and indomethacin in the treatment of rheumatoid arthritis.
Current medical research and opinion.
1976; 4(1):70-5. doi:
10.1185/03007997609109284. [PMID: 770083] - H Leach. The determination of azapropazone in blood plasma.
Current medical research and opinion.
1976; 4(1):35-43. doi:
10.1185/03007997609109279. [PMID: 1261300]